Filing Flows › Health Care › CareDx (CDNA)
CareDx (CDNA) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Oct 29, 2026 · CareDx (CDNA) Q3 2026 earnings results →
Q3 2026 Revenue up 39% year over year to $139M · 14¢ of every $1 of revenue kept as net profit · operating margin 5.8%
CareDx made $139M in Q3 2026 (+39% Y/Y): Testing services revenue $119M, Patient and digital solutions revenue $20.2M. Operating margin 5.8%, net earnings $19.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 29, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $139.4M in Q3 2026, up 39% year over year and up 6% from the previous quarter. Testing services revenue was the largest line at 86% of revenue. Testing services revenue added $47.0M year over year (up 65%), 120% of the total change.
Operating profit was $8.1M, a 5.8% margin (up 6.1 points year over year). Total costs grew 31% against revenue growth of 39%. The fastest-growing cost line was General & admin (+34%). Net earnings were $19.3M, up 1052% year over year. The effective tax rate was -80.4%. Non-operating items added $2.6M, 24% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $12.7M (down 66% year over year), 66% of net earnings. Non-cash charges added back $7.2M of depreciation and amortization and $9.7M of share-based compensation. Working capital and other items used $23.4M. Capital expenditures of $1.6M left free cash flow of $11.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Oct 29, 2026 | $139M | +39% | 5.8% | $19.3M | $12.7M |
| Q2 2026 | 10-Q | Jul 30, 2026 | $132M | +52% | 85.8% | $111M | $30.6M |
| Q1 2026 | 10-Q | Apr 28, 2026 | $118M | +39% | 1.0% | $2.8M | $4.3M |
| Q4 2025 | 10-K | Feb 25, 2026 | $108M | +25% | -5.6% | −$4.1M | $21.4M |
| Q3 2025 | 10-Q | Nov 4, 2025 | $100M | +21% | -0.2% | $1.7M | $37.4M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $86.7M | -6% | -12.8% | −$8.6M | $9.9M |
| Q1 2025 | 10-Q | Apr 30, 2025 | $84.7M | +18% | -15.8% | −$10.4M | −$26.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
- Medicare & Medicaid — 46% of its revenue · Stated in 10-K (sentence) · source
Buys from
About CareDx
CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. We deliver solutions designed to empower clinicians and improve patient outcomes. The Company's integrated solutions include non-invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics-based information for transplant patients. Our headquarters is located in Brisbane, California, and we have other primary operations in Omaha, Nebraska and Stockholm, Sweden.
In its own words, from its 10-K, filed Feb 25, 2026.
CareDx against its Services-Medical Laboratories peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +39% against the peers' median +25%. Operating margin: 5.8% against the peers' median 6.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CDNA CareDx | Q3 2026 | $139M | +39% | 5.8% |
| LH Labcorp Holdings | Q3 2026 | $3.8B | +7% | 10.6% |
| DGX Quest Diagnostics | Q3 2026 | $3.1B | +10% | 15.5% |
| NTRA Natera | Q3 2026 | $794M | +34% | -8.6% |
| FTRE Fortrea Holdings | Q3 2026 | $692M | -1% | 2.2% |
| RDNT RadNet | Q2 2026 | $623M | +25% | 6.3% |
| GH Guardant Health | Q3 2026 | $361M | +36% | -36.8% |
| CAI Caris Life Sciences | Q3 2026 | $275M | +27% | 7.0% |
| LMRI Lumexa Imaging Holdings | Q2 2026 | $264M | +5% | 8.7% |
Source: CareDx 10-Q on SEC EDGAR · CIK 1217234 · Services-Medical Laboratories
Guidance and outlook
13F: who owns CDNA and who is buying
More on CDNA
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- CareDx guidance history: guided vs reported
- CareDx operating margin by quarter
- CareDx net income by quarter
- CareDx free cash flow by quarter
- CareDx R&D spending by quarter
- CareDx capital expenditures by quarter
- CareDx Testing services revenue revenue by quarter
- CareDx Patient and digital solutions revenue revenue by quarter